Suppression in Medical Technology

Stress-Related Disorders Affect Brain's Processing of Memory

... to the healthy controls. During the memory suppression phase of the test, patients with stress-related ... cortex could be the basis for inadequate suppression of unwanted traumatic memories stored in the ... "These data suggest that the mechanism for memory suppression is dysfunctional in patients with stress-related ...

Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients

... receptor antagonist, demonstrated sustained viral suppression and increased CD4 cell counts and was ... background therapy may provide durable viral suppression and sustained elevated CD4 counts in ... CCR5 antagonist, exhibits potent, sustained suppression of viral replication in treatment-experienced ...

Research Explains How Advanced Prostate Cancer Becomes Resistant to Androgen-Deprivation Therapy

... been androgen-deprivation therapy. That is, the suppression of circulating testosterone -- the hormone that ... therapy. "We found that despite the suppression of circulating androgen levels to very low or ... it suggests we also need to target hormone suppression much more specifically, inside the tumor itself." ...

Neurocrine Biosciences Presents Elagolix Data

... of this study showed that daily administration of elagolix induced partial suppression of gonadotropins for 12-18 hours per day with a return to baseline each ... reduction of prostate weight, a reduction in epithelial proliferation and suppression of prostate growth. If these preclinical results are replicated in men, ...

Methadone Frequently Causes Menopausal Symptoms in Young Women

... A 1975 University of Pennsylvania study revealed severe hormonal suppression caused by narcotic pain medications. Despite this study, most methadone ... report physicians prescribing methadone failed to inform them of hormonal suppression risks caused by methadone. Physicians prescribing methadone, Vicodin, ...

Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy

... investigator. "There is potential value in combining the rapid, sustained suppression of testosterone that degarelix offers in this treatment. IADT appears to ... reducing and sustaining castrate levels of testosterone.(1)(2) suppression of testosterone to castrate levels occurred significantly faster in ...

ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients

... of adverse effects that limit the use of current therapies, including suppression of bone marrow function. About maribavir Maribavir is a ... the virus, their use is limited by toxicities, most notably bone marrow suppression and renal impairment. About ViroPharma Incorporated ...

Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch

... results from the trial showed there was a clear dose-response to ovulation suppression and cycle control. AG-200-15 provided the greatest ovulation suppression with the best cycle control of the three regimens studied. About Agile's ...

96-Well Filtration Plate From Varian, Inc. Improves Sensitivity and Precision for Trace Bio-Analysis by LC/MS

... chromatography/mass spectroscopy (LC/MS). Incomplete removal leads to ion suppression (reduced sensitivity) and, over time, degrades the performance of both the ... interferences (over 97% of the phosphatidylcholines are removed). Ion suppression is significantly reduced resulting in enhanced sensitivity and precision ...

Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients

... PI-containing regimen demonstrated potent and sustained viral suppression through 48 weeks of treatment.(4, 5) The standard of care for ... a next generation CCR5 antagonist, exhibits potent, sustained suppression of viral replication in treatment-experienced adults: VICTOR-E1 48-week ...

Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach

... journal articles: Nature(1) "Sequence-and target-independent angiogenesis suppression by siRNA via TLR3" Mark E. Kleinman, et. al., and Molecules and Cells(2) ... Kleinman et. al., Nature(1), "Sequence-and target-independent angiogenesis suppression by siRNA via TLR3 | doi: 10.1038/nature06765; Received published online 26 ...

Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART

... Clevudine 30 mg administered once daily demonstrated early viral suppression and significant biochemical improvement in patients with liver cirrhosis. ... (ALT). Clevudine 30 mg administered once daily demonstrated potent viral suppression and significant biochemical improvement in patients with cirrhosis. ...

NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models

... today at the 2007 AACR-NCI-EORTC Conference highlight the superior tumor suppression properties of NKTR-102 relative to irinotecan in colorectal, lung and ... models, NKTR-102 inhibited tumor growth at all dose levels with 94% tumor suppression at the highest dose of 90 mg/kg relative to controls. Tumor regression was ...

Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses

... studies that are many-fold above concentrations needed for viral suppression is generally recognized as a predictor of potential clinical utility." In ... blood levels that are many-fold above plasma levels needed for viral suppression is generally recognized as a predictor of potential clinical utility, and ...

New Results From ARTEN Study of Nevirapine Plus Tenofovir and Emtricitabine (TDF/FTC) Versus Boosted Protease Inhibitor Regimen of Atazanavir/Ritonavir Plus TDF/FTC Revealed

... at 48 weeks of treatment, with response defined as a viral load of <50 copies/mL measured at two consecutive visits prior to week 48 (i.e. suppression at weeks 24 and 36) and without subsequent rebound or change of therapy prior to week 48. In the primary analysis of the primary endpoint, the two ...

Orexigen(R) Therapeutics Schedules July 20, 2009 Teleconference and Webcast Discussion of Contrave(R) Phase 3 Results

... over time. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the Company can be found at www.orexigen.com . ...

Proteolix, Inc. Drug Candidate, PR-957, Prevents Disease Progression in Rheumatoid Arthritis Models by Selective Inhibition of the Immunoproteasome

... compared to that achieved with non-selective proteasome inhibitors, and can have dramatic impact on the inflammatory response without risking broad suppression of immune system function." Proteolix plans to file an Investigational New Drug Application for PR-957 in mid-2010. "The research ...

Anthera's Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome

... of secretory phospholipase A2 (sPLA2), has demonstrated marked improvements in independent markers of cardiovascular risk including, a near complete suppression of sPLA2 activity and mass, clinically meaningful and statistically significant reduction in LDL cholesterol, and a reduction in C-reactive protein. ...

Medarex Announces Preclinical Data from Multiple Research Programs Demonstrating Anti-Tumor Activity in Cancer

... specificity, effector function and internalization properties. MDX-1414 demonstrated anti-tumor efficacy leading to significant and durable suppression of established subcutaneous tumors in a liver cancer xenograft model with no evidence of toxicity. Targeting glypican-3 with antibodies enhanced for ...

Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis

... vs. 2.5 percent, and 5.1 percent vs. 0 percent, respectively; p less than or equal to 0.005). "The significant increases in BMD and suppression of markers of bone turnover seen in these data show the potential benefits of arzoxifene for the treatment of osteoporosis in postmenopausal women," ...

New Cancer Treatment Stops Aggressive Sarcomas

... cancer treatment. Most patients never experience effects commonly affiliated with chemotherapy or radiation (nausea, vomiting, hair loss, bone marrow suppression or immune system suppression). An experienced physician prescribes and monitors the outpatient treatment. A web site, www.neoplas.org , ...

Rosetta Genomics Reports First Ever In-Vivo Efficacy Data for a Systemic MicroRNA Therapeutic for Liver Cancer

... ) reported today the first ever in-vivo efficacy data for a systemic microRNA-based cancer therapeutic. The animal-model study demonstrated a marked suppression of a microRNA that was found to be over expressed in human hepato-cellular carcinoma (HCC), and a significant two-fold reduction of tumor mass. These ...

ESBATech's Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity

... to traditional TNF alpha inhibitors. This is a crucial point in OA, which is a non-life-threatening, rather local disease. Therefore, systemic suppression of TNF alpha, as achieved by marketed TNF alpha inhibitors and associated with various safety issues, is not justified for osteoarthritis patients. ...

Dacogen(R) (decitabine for injection) Data Presented on a Phase II Clinical Trial in Elderly Patients with Acute Myeloid Leukemia (AML)

... of the disease progression. Induction chemotherapy, the standard front-line AML therapy, is associated with high toxicity, including bone marrow suppression and increased risk of infection, which often limits use in elderly patients with a poor prognosis. About Dacogen (R) ...

Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team

... Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the company can be found at http://www.orexigen.com . Forward-Looking Statements ...

Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union

... medical need for thousands of patients in the European Union as it is a unique treatment option that increases platelet production and avoids immune suppression in adult chronic ITP patients," said Willard Dere, M.D., senior vice president and international chief medical officer at Amgen. The novel ...

Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy

... of the study said, "RNAi-mediated reduction of Nrf2 expression represents a potential breakthrough for treating non-small cell lung cancer. suppression of Nrf2 effectively inhibited tumor growth and increased sensitivity to chemotherapeutic drug-induced cell death in the study. It is critical that we ...

Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval

... of secretory phospholipase A2 (sPLA2), has demonstrated marked improvements in independent markers of cardiovascular risk including, a near complete suppression of the target enzyme sPLA2, clinically meaningful and statistically significant reductions in "bad" LDL cholesterol, and a reduction in C-reactive ...

Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients

... of IDX899 and no patients discontinued the study. "We are pleased that HIV-1-infected patients receiving IDX899 in this trial achieved potent viral suppression at all doses tested," said Douglas Mayers, M.D., Idenix's chief medical officer. "With the promising antiviral activity and safety profile seen to ...

Isis Initiates Clinical Trial of CRP Drug

... as end-stage renal disease, suggesting that lowering CRP in these patients would be beneficial. In preclinical studies, ISIS 353512 produced dramatic suppression of liver and serum CRP levels. ABOUT ISIS PHARMACEUTICALS, INC. Isis is exploiting its expertise in RNA to discover and develop novel drugs for ...

Innocoll Announces Dosing of Last Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-Operative Pain

... controlled with narcotic analgesics such as morphine, but systemic administration of these drugs can result in unfavorable side effects including suppression of breathing, sedation, nausea and vomiting, and can also affect patient recovery. Innocoll's BUPIVACAINE SURGICAL IMPLANT is intended to provide ...

Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines

... showed that regardless of gender or race, Kaletra dosed once-daily or twice-daily as part of a treatment regimen achieved consistent virologic suppression in patients new to antiretroviral therapy," said Scott Brun, M.D., divisional vice president, Infectious Diseases and Immunology Development, Global ...

Eight-Year Melanoma Remission is Among Early Cancer Treatment Results

... is fatigue. Most patients never experience side effects commonly affiliated with chemotherapy or radiation (nausea, vomiting, hair loss, bone marrow suppression or immune system suppression). An experienced physician prescribes and monitors all treatment and maintains close communication with the patient's ...

Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients' Day

... or adolescents with ADHD, patients beginning treatment should be monitored for the appearance of or worsening of aggressive behavior or hostility. suppression of growth has been reported with long-term use of stimulants. Stimulants should be used with caution in patients with a prior history of seizures or ...

Biopure Announces Meeting With FDA

... by the patient," said Zafiris G. Zafirelis, Biopure CEO and President. "By serving as an oxygen delivery bridge following chemotherapy-induced suppression of red blood cell count, use of Hemopure, as part of a bloodless treatment regimen, may potentially reduce mortality in these patients, who ...

Positive Phase I/II Data of IDX899 Confirm Potent Antiviral Activity and Favorable Safety Profile in Treatment-Naive HIV-Infected Patients

... Feinberg School of Medicine, Northwestern University. "These early clinical data are very encouraging, showing that IDX899 offers potent viral suppression combined with a promising safety profile." Study Design The phase I/II clinical trial was designed to evaluate the safety, tolerability, ...

Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients

... for Children Act. Clolar should be administered under the supervision of a qualified physician experienced in the use of antineoplastic therapy. suppression of bone marrow function, which is usually reversible and dose dependent, should be anticipated and is likely to increase the risk of ...

Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)

... may prove to be a more powerful and tolerable anti-tumor agent. Preclinical studies show that treatment with NKTR-102 results in significant suppression of tumor growth in an irinotecan-resistant mouse colorectal tumor model and in similar models of breast and lung cancer. Administration of NKTR-102 ...

Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting

... cell death 1), a receptor expressed on the surface of activated lymphocytes (T-cells) that is involved in the system of negative regulation for the suppression of activated lymphocytes. Preclinical studies suggest that blockade of the PD-1 signaling pathway by MDX-1106/ONO-4538 activates T-cell responses ...

ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients

... While currently available systemic anti-CMV agents are effective against the virus, their use is limited by toxicities, most notably bone marrow suppression and renal impairment. About ViroPharma Incorporated ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and ...